The Assessment of Infrared Treatment for Crohn's Disease

Condition(s) studied

Investigational drug(s) / intervention(s)

High level photobiomodulation treatment in the infrared (IR) range.: The baseline treatment included 10 weekly 30 minutes long sessions of high level fIR treatment.

Medium level photobiomodulation treatment in the far infrared (IR) range: The baseline treatment included 10 weekly 30 minutes long session of medium level fIR treatments

Low level photobiomodulation treatment in the far infrared (IR) range: The baseline treatment included 10 weekly 30 minutes long session of low level fIR treatments

Photobiomodulation sham treatment: The baseline treatment includes 10 weekly 30 minutes long of sham fIR treatment.

Study summary

The goal of this clinical trial is to test the safety and efficacy of far Infra-red (fIR) therapy in Crohn's disease patients.

The main questions it aims to answer are:

1. Is infrared therapy safe for treating Crohn's disease patients?
2. Is infrared therapy effective for treating Crohn's disease?

Participants will be asked to attend 10 treatments of fIR therapy, provide stool and blood samples and answer questionnaires.

Researchers will compare between 4 treatments: three intensities of fIR therapy and placebo treatment to explore which intensity is most effective for treating Crohn's disease.

Eligibility

Primary outcome measure(s)

• Assess the safety of fIR therapy for CD patients. — 2 years
  The investigator will document all adverse events and assess their severity. The only documented adverse event for fIR treatment in the currently available literature are first degree burns. Hence, the treatment will be considered safe if no additional adverse events will occur. Clinical and biochemical markers will be monitored for the possibility of disease exacerbation following fIR treatment.

Trial sites (1)

More Shmuel Kivity, MD trials in Israel

Other trials for the same condition